After reporting second-quarter results that contained upbeat clinical news, Spark Therapeutics (NASDAQ: ONCE), a clinical-stage company focused on gene therapy, rose 18% as of 12:30 p.m. EDT on Wednesday.
Here’s a review of the key highlights from the quarter that have traders feeling giddy today: